Table 1.
Baseline characteristics at diagnosis
| Variable | Patients (n = 87) |
|---|---|
| Male sex, n (%) | 71 (82) |
| Age, median (range) | 63 (40–79) |
| Non-clear cell pathology, n (%) | 17 (20) |
| WHO performance status, n (%) | |
| 0–1 | 82 (94) |
| 2–4 | 5 (6) |
| More than one metastatic site, n (%) | 48 (55) |
| Liver metastasis, n (%) | 15 (17) |
| Lung metastasis, n (%) | 48 (56) |
| Bone metastasis, n (%) | 21 (24) |
| Brain metastasis, n (%) | 3 (3) |
| Haemoglobin < LLN, n (%) | 46 (52) |
| Neutrophil count > ULN, n (%) | 18 (21) |
| Platelet count > ULN, n (%) | 19 (22) |
| Corrected serum calcium > ULN, n (%) | 26 (30) |
| Lactate dehydrogenase >1.5 times ULN, n (%) | 11 (12) |
| Time since RCC diagnosis <1 year | 78 (90) |
| MSKCC risk score, n (%) | |
| Favourable | 6 (7) |
| Intermediate | 54 (62) |
| Poor | 27 (31) |
LLN lower limit of normal, ULN upper limit of normal, RCC renal cell carcinoma, MSKCC Memorial Sloan Kettering Cancer Center